Cargando…

Comparison of clinical and survival characteristics between prostate cancer patients of PSA-based screening and clinical diagnosis in China

Prostate-specific antigen (PSA)-based mass screening remains the most controversial topic in prostate cancer. PSA-based mass screening has not been widely used in China yet. The aim of our study was to evaluate the effect of the PSA-based screening in China. The cohort consisted of 1,012 prostate ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Libo, Wang, Jinguo, Guo, Baofeng, Zhang, Haixia, Wang, Kaichen, Wang, Ding, Dai, Chang, Zhang, Ling, Zhao, Xuejian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787478/ https://www.ncbi.nlm.nih.gov/pubmed/29416625 http://dx.doi.org/10.18632/oncotarget.20787

Ejemplares similares

Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline
por: Tikkinen, Kari A O, et al.
Publicado: (2018)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Characteristics of α2,3‐sialyl N‐glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level
por: Yoneyama, Tohru, et al.
Publicado: (2021)

Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial
por: Nam, Robert, et al.
Publicado: (2022)

Metastatic prostate cancer in the modern era of PSA screening
por: Fontenot, Philip A., et al.
Publicado: (2017)

Genetically adjusted PSA levels for prostate cancer screening
por: Kachuri, Linda, et al.
Publicado: (2023)

Clinical Use of [-2]proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
por: Abrate, Alberto, et al.
Publicado: (2014)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

Synthetic CRISPR/dCas9-KRAB system driven by specific PSA promoter suppresses malignant biological behavior of prostate cancer cells through negative feedback inhibition of PSA expression
por: Yang, Yi, et al.
Publicado: (2023)

Using “Age and Total-PSA” as the Main Indicators: The Results of Taizhou Integrated Prostate Screening (No 2)
por: Zhu, Xiao-Liang, et al.
Publicado: (2023)

Mean Platelet Volume Enhances the Diagnostic Specificity of PSA for Prostate Cancer
por: Song, Wei, et al.
Publicado: (2022)

Effect of Body mass index on the performance characteristics of PSA-related markers to detect prostate cancer
por: Zhu, Yao, et al.
Publicado: (2016)

Seminal citrate is superior to PSA for detecting clinically significant prostate cancer
por: Gregório, Emerson Pereira, et al.
Publicado: (2019)

Screening for Prostate Cancer by Digital Rectal Examination and PSA Determination in Senegal
por: Niang, Lamine, et al.
Publicado: (2011)

Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening
por: Koo, Kevin, et al.
Publicado: (2017)

Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI
por: Ma, Zengni, et al.
Publicado: (2023)

Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone
por: Liu, Junxiao, et al.
Publicado: (2020)

Investigation of awareness rate of prostate-specific antigen (PSA) among the general public in China and analysis of influencing factors
por: Wang, Yuqin, et al.
Publicado: (2023)

PSA screening – for whom and when?
por: Albers, Peter
Publicado: (2019)

Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators
por: Liu, Xiaomin, et al.
Publicado: (2023)

Yinglu Guo: PSA screening test requires wider application in China
por: Song, Xiaoping
Publicado: (2012)

Characteristics of PSA Bounce after Radiotherapy for Prostate Cancer: A Meta-Analysis
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2020)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0–25.0 ng ml(-1) in Western China
por: Gao, Xue-Dan, et al.
Publicado: (2021)

A Neural Network Model Combining [-2]proPSA, freePSA, Total PSA, Cathepsin D, and Thrombospondin-1 Showed Increased Accuracy in the Identification of Clinically Significant Prostate Cancer
por: Gentile, Francesco, et al.
Publicado: (2023)

Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening
por: Jen, Hsiao-Hsuan, et al.
Publicado: (2020)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml(–1)
por: Wang, Cheng, et al.
Publicado: (2021)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II
por: Nakajima, Kosei, et al.
Publicado: (2016)

Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis
por: Ilic, Dragan, et al.
Publicado: (2018)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

To be screened or not to be screened? Modeling the consequences of PSA screening for the individual
por: Wever, E M, et al.
Publicado: (2012)

Value of machine learning-based transrectal multimodal ultrasound combined with PSA-related indicators in the diagnosis of clinically significant prostate cancer
por: Zhang, Maoliang, et al.
Publicado: (2023)

Long-Term Survival and PSA Control with Radiation and Immunotherapy for Node Positive Prostate Cancer
por: Kamrava, M., et al.
Publicado: (2009)

A novel clinically significant prostate cancer prediction system with multiparametric MRI and PSA: P.Z.A. score
por: Chen, Zongxin, et al.
Publicado: (2023)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Practice Patterns of Korean Urologists for Screening and Managing Prostate Cancer according to PSA Level
por: Chung, Mun Su, et al.
Publicado: (2012)

Evaluation of a rapid one-step PSA test for primary prostate cancer screening
por: Ashida, Shingo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pb40neslkat6egtkg0tbmlrat4